

ROMOSOZUMAB solution for injection (EVENTITY® ▼) for treating severe osteoporosis

The Pan Mersey Area Prescribing Committee recommends the prescribing of ROMOSOZUMAB solution for injection (EVENTITY® ▼), by specialists only, for treating severe osteoporosis in accordance with NICE TA791.

RED

[NICE technology appraisal \(TA\) 791](#) (25 May 2022)^[1] recommends romosozumab as an option for treating severe osteoporosis in people after menopause who are at high risk of fracture, only if:

- > they have had a major osteoporotic fracture (spine, hip, forearm or humerus fracture) within 24 months (so are at imminent risk of another fracture) **and**
- > the company provides romosozumab according to the commercial arrangement.^[1]

Treatment should be initiated by a specialist experienced in the diagnosis and treatment of osteoporosis. Prescribing and monitoring should be retained by the specialist.

Based on the NICE Resource Impact Template for NICE TA791, the estimated cost of implementing this guidance is £24,000 per 100,000 population in 2022/23, rising to £62,000 per 100,000 population by 2026/27 when it is assumed that steady state has been reached. This is based on the NHS list price and includes any additional administration costs as well as additional drug costs. The resource impact will be less once the PAS discount is applied.

References

1. National Institute for Health and Care Excellence. Technology Appraisal 791: [Romosozumab for treating severe osteoporosis](#), 25 May 2022. Accessed 06 June 2022.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.